remacemide has been researched along with Akinetic-Rigid Variant of Huntington Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejewski, KL; Atassi, N; Auinger, P; Banno, H; Cudkowicz, ME; de Blieck, EA; Majumder, M; McDermott, MP; Murphy, A | 1 |
| Bates, GP; Hockly, E | 1 |
| Almqvist, EW; Aylward, EH; Field, K; Hayden, M; Kieburtz, K; McDermott, M; Raymond, LA; Rosenblatt, A; Ross, CA; Yallapragada, V | 1 |
| Borchelt, DR; Chan, N; Coonfield, ML; Eaton, M; Fromholt, D; Gale, A; Morton, JL; Neslon, C; Ross, CA; Savonenko, AV; Schilling, G; Vorovich, E | 1 |
| Abwender, D; Claude, K; Como, P; Dunn, C; Feigin, A; Greenamyre, JT; Hickey, C; Kieburtz, K; McDermott, M; Orme, C; Shoulson, I; Sotack, J; Zimmerman, C | 1 |
| Kieburtz, K | 1 |
| Schachter, SC; Tarsy, D | 1 |
| Borchelt, DR; Coonfield, ML; Ross, CA; Schilling, G | 1 |
| Andreassen, OA; Beal, MF; Dedeoglu, A; Ferrante, KL; Ferrante, RJ; Hersch, SM; Jenkins, BG | 1 |
3 review(s) available for remacemide and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Topics: Acetamides; Animals; Antioxidants; Creatine; Disease Models, Animal; Evaluation Studies as Topic; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Peptides; Point Mutation; Riluzole; Thioctic Acid; Trinucleotide Repeats; Ubiquinone | 2003 |
Antiglutamate therapies in Huntington's disease.
Topics: Acetamides; Excitatory Amino Acid Antagonists; Genes, Dominant; Humans; Huntington Disease; Neuroprotective Agents; Trinucleotide Repeats | 1999 |
Remacemide: current status and clinical applications.
Topics: Acetamides; Animals; Anticonvulsants; Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Intraoperative Complications; Neuroprotective Agents; Parkinson Disease; Phenethylamines; Receptors, N-Methyl-D-Aspartate | 2000 |
4 trial(s) available for remacemide and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study.
Topics: Acetamides; Antioxidants; Caudate Nucleus; Coenzymes; Humans; Huntington Disease; Longitudinal Studies; Magnetic Resonance Imaging; Male; Neuroprotective Agents; Neuropsychological Tests; Pilot Projects; Radiography; Treatment Outcome; Ubiquinone | 2003 |
A controlled trial of remacemide hydrochloride in Huntington's disease.
Topics: Acetamides; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Huntington Disease; Male; Middle Aged; Neurologic Examination; Neuroprotective Agents; Neuropsychological Tests; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 1996 |
Antiglutamate therapies in Huntington's disease.
Topics: Acetamides; Excitatory Amino Acid Antagonists; Genes, Dominant; Humans; Huntington Disease; Neuroprotective Agents; Trinucleotide Repeats | 1999 |
A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
Topics: Acetamides; Adult; Coenzymes; Double-Blind Method; Female; Humans; Huntington Disease; Male; Middle Aged; Prognosis; Time Factors; Ubiquinone | 2001 |
4 other study(ies) available for remacemide and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.
Topics: Acetamides; Female; Humans; Huntington Disease; Kaplan-Meier Estimate; Male; Middle Aged; Minocycline; Neuroprotective Agents; Neuropsychological Tests; Patient Dropouts; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ubiquinone | 2017 |
Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Topics: Acetamides; Animals; Celecoxib; Chlorpromazine; Coenzymes; Cyclooxygenase Inhibitors; Disease Models, Animal; Disease Progression; Dopamine Antagonists; Environment, Controlled; Female; Humans; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Motor Skills; Neuroprotective Agents; Phenotype; Pyrazoles; Sulfonamides; Superoxide Dismutase; Superoxide Dismutase-1; Survival Rate; Treatment Outcome; Ubiquinone | 2004 |
Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.
Topics: Acetamides; Animals; Antioxidants; Coenzymes; Drug Therapy, Combination; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Nerve Tissue Proteins; Nuclear Proteins; Peptide Fragments; Survival Analysis; Time Factors; Ubiquinone | 2001 |
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Topics: Acetamides; Administration, Oral; Animals; Behavior, Animal; Body Weight; Brain; Cerebral Ventricles; Coenzymes; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Huntingtin Protein; Huntington Disease; Magnetic Resonance Imaging; Male; Mice; Mice, Transgenic; Motor Activity; Nerve Tissue Proteins; Nuclear Proteins; Organ Size; Survival Rate; Treatment Outcome; Ubiquinone | 2002 |